Programs and Events
R & D Enterprises, LLC
goes to many different science-related programs and events that are featured on the webpage. Recent news, new developments and advancements are constantly made in the science world, so R & D will keep updates posted on the site.

 

Press Releases

R&D Enterprises Files First IND for Biogeneric Insulin
-New Manufacturing Process Expected to Dramatically Reduce the Cost to Patients -

(Greenwood, Ind. – March 4, 2010) – R&D Enterprises, LLC, a subsidiary of Elona Biotechnologies, Inc., announced today that it has filed an IND with the FDA for a biogeneric form of insulin which, if approved, is expected to significantly reduce the cost of insulin for diabetic patients in the U.S. and eventually around the world.
“We have developed a unique, proprietary and iterative system that utilizes improved cell banking and protein expression technology which has significantly enhanced purification yields,” said Ron Zimmerman Sr., President of Elona. “If approved, this product will offer a high quality, low cost option to patients who otherwise cannot afford insulin,” he said.

Read entire Press Release:

  
     ELONA Biotechnologies, Inc. is a technology leader in proteomics, process development, characterization and production of therapeutic proteins.  With offices, laboratories and production facilities located south of Indianapolis, the company is involved in the development and production of human insulin, insulin analogs, human growth hormone and other “follow-on” proteins which treat chronic diseases.  ELONA has a unique portfolio of intellectual property and the capability to produce Active Pharmaceutical Ingredients and protein Drug Products under cGMP conditions.  Through collaborative ventures with industry partners and leading academic institutions ELONA’s skilled team of scientists develops, operates and licenses innovative production processes for both novel and bioequivalent protein products.

  

Elona Biotechnoligies Launches New Operating Subsidiaries (May 28, 2009)

  Greenwood, IN – Elona Biotechnologies, Inc. announced today that it has formed two new operating subsidiaries to facilitate growth in its biosimilar, biogeneric, follow-on protein business.  R&D Enterprises, LLC will develop and commercialize Elona’s technology and Zimmerman Biotechnologies, LLC will manufacture protein products.

  “Creation of these two new subsidiaries marks an important milestone for Elona and for our clients,” said Ron Zimmerman, founder and president of the company. “We now have the ability to go all the way from the gene through a formulated drug product.  R&D Enterprises will continue to develop, license and pursue regulatory approvals.  The new Zimmerman Biotechnologies subsidiary will manufacture commercial quantities of Active Pharmaceutical Ingredients (API) and commercialize our company’s innovative technology in the established multi-billion dollar markets for Drug Products made using recombinant proteins.  These new subsidiaries will focus our efforts to meet the surge in demand for our services as world markets demand biogeneric protein products.”



  
  HOME | PRINCIPALS | CAPABILITIES | EQUIPMENT | ACCOMPLISHMENTS | NEWS | CONTACT